Cornerstone Therapeutics, Digestive Care sales and marketing update

Cornerstone launched Pertzye pancrelipase in the U.S. to treat exocrine pancreatic insufficiency due to cystic fibrosis. A 100-dose package of Pertzye has a wholesale acquisition cost of $159 for an ...